(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.27%) $79.16
(-0.74%) $2.02
(0.03%) $2 310.40
(0.19%) $26.88
(0.32%) $965.70
(-0.06%) $0.932
(-0.10%) $10.98
(-0.13%) $0.797
(1.50%) $92.50
@ $3.64
Išleistas: 13 vas. 2024 @ 22:55
Grąža: 2.34%
Ankstesnis signalas: vas. 9 - 20:51
Ankstesnis signalas:
Grąža: -3.84 %
Live Chart Being Loaded With Signals
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders...
Stats | |
---|---|
Šios dienos apimtis | 266 868 |
Vidutinė apimtis | 461 352 |
Rinkos kapitalizacija | 215.55M |
EPS | $0 ( 2024-04-01 ) |
Kita pelno data | ( $-0.580 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.330 |
ATR14 | $0.00700 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-25 | Demopulos Gregory A Md | Buy | 725 000 | Stock Option (right to buy) |
2024-04-25 | Jacobsen Michael A | Buy | 100 000 | Stock Option (right to buy) |
2024-04-25 | Cancelmo Peter B | Buy | 100 000 | Stock Option (right to buy) |
2023-11-17 | Demopulos Gregory A Md | Buy | 15 000 | Common Stock |
2023-11-15 | Demopulos Peter A Md | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
98.87 |
Last 99 transactions |
Buy: 4 085 039 | Sell: 554 578 |
Tūris Koreliacija
Omeros Corp Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Omeros Corp Koreliacija - Valiuta/Žaliavos
Omeros Corp Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-920 000 (0.00 %) |
EPS: | $-1.880 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-920 000 (0.00 %) |
EPS: | $-1.880 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-952 000 (0.00 %) |
EPS: | $0.460 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $3.12 |
Financial Reports:
No articles found.
Omeros Corp
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.